Evidence map›Paper›PMID 33971620›Full record

ArticleAging2021

Plasma hemoglobin and the risk of death in HIV/AIDS patients treated with antiretroviral therapy.

Dayong Wang, Xiangqing Hou, Xianghua Yu, Tao Wang, Zhenmiao Ye, Jushuang Li, Feifei Su, Chengnan Guo, Fang Peng, Shuzhen Zhao and 10 more

Open access · greenAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Dayong WangWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Xiangqing HouDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Xianghua YuWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Tao WangDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Zhenmiao YeWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Jushuang LiDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Feifei SuThe Sixth People's Hospital of Wenzhou, Wenzhou 325035, Zhejiang, China.
Chengnan GuoDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Fang PengDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Shuzhen ZhaoDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Huihui LiDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Jingjing ZuoSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
Dehua SuWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Lina ZhaoWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Hemei ZhangWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Xiangyang ChenWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Ruoqiu WangWenzhou Center for Disease Control and Prevention, Wenzhou 325000, Zhejiang, China.
Qipeng XieThe Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
Chao ZhengThe Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.
Guangyun MaoDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Wenzhou Medical University · CNZhejiang Center for Disease Control and Prevention · CNSecond Affiliated Hospital of Zhejiang University · CNUniversity of Macau · MOWenzhou City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies concerning the effect of plasma hemoglobin (HB) and other factors that may modify the risk of death in people living with HIV/AIDS (PLHIV) treated with antiretroviral therapy (ART) are limited.

resultsHigher HB was independently linked to a lower death risk in PLHIV, with a decrease of 29% (13%, 43%) per standard deviation (SD) increment after adjusting for CD4, VL and other potential factors [hazard ratio (HR): 0.71, 95% confidence interval (CI): 0.57-0.87, P<0.001]. In addition, the addition of HB to the predictive model containing VL and CD4 significantly improved the C-index, by 0.69% (95% CI: 0.68%-0.71%), and net discrimination, by 0.5% (95% CI: 0.0%-1.6%, P=0.040), when predicting the death risk of PLHIV.

conclusionsA lower level of HB was an independent risk factor for HIV/AIDS-associated death in PLHIV. HB combined with VL and CD4 may be an appropriate predictive model of the death risk of PLHIV. MATERIALS AND

methodsA propensity-score matching (PSM) approach was applied to select a total of 750 PLHIV (150 deceased and 600 living) from the AIDS prevention and control information system in the Wenzhou area from 2006 to 2018. Multivariable Cox proportional hazards regression models were formulated to estimate the effect of HB. The predictive performance improvement contributed by HB was evaluated using the C-index and net reclassification improvement.

Indexed as

Acquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsFemaleHemoglobinsHIV InfectionsHumansMaleProportional Hazards ModelsRisk FactorsAnti-Retroviral AgentsHemoglobinsC-indexHBHIV/AIDS associated deathinteractionnet discrimination

Identifiers

PMID33971620
PMCPMC8148493
OpenAlexW3160849686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.